Explains the fluttery 'skipped-beat' sensation many coffee-drinkers notice — premature ventricular complexes (PVCs) and atrial ectopy that the conscious heart-tap registers as a pause-then-thud. Caffeine is a competitive antagonist at adenosine A1 and A2A receptors at ordinary intake concentrations (Fredholm 1999). Endogenous adenosine, acting on A1 receptors at the sinoatrial and atrioventricular nodes, slows automaticity and conduction — this is the mechanism behind IV adenosine as the drug of choice for terminating SVT (DiMarco 1990). When caffeine blocks A1, the tonic adenosinergic brake on nodal pacemaking is lifted, which combined with secondary catecholamine release (β1 → cAMP → PKA → If/IK shifts) raises ectopy in susceptible substrates. The 2023 CRAVE trial (Marcus 2023) is the cleanest prospective data: a randomized day-on / day-off design in 100 ambulatory adults showed coffee days had measurably more PVCs (though fewer atrial ectopic beats — the atrial story is more nuanced). CYP1A2 polymorphism gates exposure: slow metabolizers (CYP1A2*1F) accumulate caffeine longer and show stronger cardiovascular responses (Cornelis 2006 linked slow metabolizer + heavy coffee to MI risk). Effect is dose-dependent and tachyphylactic — habituated users have upregulated A1 receptors and largely lose the ectopy response. Importantly, the prospective evidence does NOT support clinical atrial-fibrillation risk from moderate coffee intake (Klatsky 2011 review); the user-felt 'skipped beats' are mostly benign PVCs amplified by caffeine-driven sympathetic tone.
Organ Systems
cardiovascular
nervous
Pathway Steps
caffeine → A1 / A2A adenosine receptor antagonism — via competitive antagonism at A1 (cardiac nodal) and A2A (vascular + cortical) at intake-relevant concentrations. Caffeine’s cardiac effects begin with competitive antagonism of adenosine A1 and A2A receptors — it is a structural analog of adenosine. At ordinary dietary doses this receptor blockade (not phosphodiesterase inhibition, which needs far higher levels) is the dominant mechanism behind caffeine’s actions.
A1 / A2A adenosine receptor antagonism → loss of tonic adenosinergic brake on SA + AV nodes — via A1 normally slows SA pacemaking + AV conduction via Gi → ↓cAMP → ↓If, ↓ICa-L (mirror of IV adenosine in SVT). Adenosine normally exerts a tonic inhibitory “brake” on the SA and AV nodes — slowing rate and conduction, the basis of using IV adenosine to terminate SVT. By blocking A1 receptors, caffeine removes this brake, nudging the conduction system toward faster, more excitable behavior.
loss of tonic adenosinergic brake on SA + AV nodes → secondary catecholamine release + raised sympathetic tone — via central A1 antagonism + peripheral sympathetic outflow rise → mild β1 stimulation → ↑pacemaker automaticity. Losing the adenosinergic brake also raises sympathetic tone and secondary catecholamine release, further increasing automaticity and the chance of ectopic beats. This sympathetic arm is why caffeine’s cardiac effects are amplified by stress, sleep deprivation, or other stimulants.
secondary catecholamine release + raised sympathetic tone → increased PVCs / premature atrial complexes — via CRAVE trial day-on/day-off: coffee days had more PVCs; atrial ectopy direction less consistent (Marcus 2023). The net result is a greater tendency to premature ventricular contractions (PVCs) and premature atrial complexes — ectopic beats arising outside the normal pacemaker. Notably, large studies (and a randomized NEJM coffee trial) show this effect is modest and inconsistent, so routine caffeine restriction for ectopy is often unwarranted.
increased PVCs / premature atrial complexes → palpitations / "skipped beats" sensation — via conscious detection of post-ectopic compensatory pause + stronger contraction; benign in normal hearts. Ectopic beats are felt as palpitations or “skipped beats” — the compensatory pause after a PVC and the forceful next beat are what the person actually notices. The sensation’s intensity correlates poorly with arrhythmic risk, which is usually benign in structurally normal hearts.
Known Modulators
caffeine (inhibitor) — adenosine A1 receptor (cardiac nodal tissue). the perpetrator — competitive A1 antagonism at intake-relevant concentrations; CYP1A2 slow metabolizers (*1F variant) accumulate higher plasma levels and show stronger cardiovascular response (Cornelis 2006). Chronic intake upregulates A1 receptors → tachyphylaxis for the ectopy effect
adenosine (activator) — A1 receptor (the displaced endogenous ligand). the agonist caffeine displaces; IV adenosine bolus is the clinical mirror — exploits the same A1-mediated AV nodal block to terminate paroxysmal SVT (DiMarco 1990)